Fingerprint
Dive into the research topics of 'C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the North Central Cancer Treatment Group N9831 adjuvant trastuzumab trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically